Ali Zubair

Dr. Ali Zubair

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2025 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
Ali ZubairAli Zubair
Ali Zubair
MAMuhammad Arham
Muhammad Arham
SKSaif Ali Khan
Saif Ali Khan
HTHaseeb Tareen
Haseeb Tareen
ADAllah Dad
Allah Dad
HAHafsa Ahmed
Hafsa Ahmed

3 November 2025 in Blood
Verified
Journal Article
Closed access
HTHaseeb Tareen
Haseeb Tareen
ADAllah Dad
Allah Dad
UMUsman Mazhar
Usman Mazhar
SKSaif Ali Khan
Saif Ali Khan
KBKinza Bakht
Kinza Bakht
AIAhmad Iftikhar
Ahmad Iftikhar
Background: Acute myeloid leukemia (AML) remains a highly fatal hematologic malignancy among older adults in the United States. Despite the availability of novel therapies, the long-term epidemiological trends across demographic subgroups remain poorly defined. This study aimed to evaluate temporal trends in AML-related mortality among adults aged ≥65 years in the U.S. from 1979 to 2023, stratified by sex, race, and Census region, and to forecast mortality through 2050.Methods: AML-related deaths were identified using ICD-9 code 205.0 and ICD-10 code C92.0 from the CDC WONDER database. Age-adjusted mortality rates (AAMRs) per million were calculated for each subgroup. Joinpoint regression was used to estimate average annual percent changes (AAPCs) and significant trend shifts (APCs). To forecast mortality through 2050, Box-Cox ARIMA models were developed after stationarity testing using the ADF and KPSS tests. Results: Between 1979 and 2023, a total of 224,418 AML-related deaths occurred among U.S. adults aged ≥65. The AAMR increased from 107.8 per million (95% CI: 103.5–112) in 1979 to 149.2 per million (95% CI: 146–152.5) in 2023. The AAPC was +0.72% (95% CI: 0.52%–0.93%; p < 0.001). Joinpoint analysis identified four distinct periods. A decline from 1979–1989 (APC –0.75%; 95% CI: –1.31% to –0.19%; p = 0.01), a sharp rise from 1989–2002 (APC +2.52%; 95% CI: 2.16%–2.88%; p < 0.001), a continued rise from 2002–2011 (APC +1.17%; 95% CI: 0.62%–1.73%; p = 0.0001), and a modest decline from 2011–2023 (APC –0.30%; 95% CI: –0.55% to –0.04%; p = 0.02). Males exhibited significantly higher AML-related mortality rates than females, with an overall AAMR of 178.86 per million (95% CI: 171.83–184.89) compared to 98.66 per million in females (95% CI: 94.43–102.90). Regionally, The Midwest had the highest AAMR of 142.03 (95% CI: 134.04–150.02), followed by the West (132.10), Northeast (131.56), and South (123.54). All regions experienced significant long-term increases in mortality, with the Midwest exhibiting the steepest rise (AAPC: +0.82%, 95% CI: 0.50–1.19, p<0.000001). White individuals had the highest AAMR at 136.59 per million, followed by Asian/Pacific Islanders (99.2), Black or African American individuals (92.8), and American Indian/Alaska Natives (74.4). AML mortality rates increased significantly across all racial groups. The steepest rise was observed in Black or African American individuals (AAPC:+1.29%, 95% CI: 1.06 to 1.52). Forecasting models project a continued increase inAAMR, reaching approximately 191.4 per million by 2050 (95% CI: 157.7–225.1), suggesting a sustained disease burden despite recent declines. Conclusion: Despite recent modest declines, AML-related mortality among U.S. adults aged ≥65 has increased significantly over the past four decades, with persistent disparities across sex, race, and region. Forecasting models project a continued upward trend, with the age-adjusted mortality rate expected to reach approximately 191.4 per million by 2050. These findings highlight the urgent need for targeted prevention strategies, improved access to novel therapies, and focused public health interventions to address the growing burden of AML in the aging population.

3 November 2025 in Blood
Verified
Journal Article
Closed access
HTHaseeb Tareen
Haseeb Tareen
ADAllah Dad
Allah Dad
MVMaha Veer
Maha Veer
JEJahnavi Ethakota
Jahnavi Ethakota
SBSakshi Bai
Sakshi Bai
VGVenumadhavi Gogineni
Venumadhavi Gogineni
Background: Myelodysplastic Syndromes (MDS) are clonal hematopoietic neoplasms that lead to dysplasia and ineffective hematopoiesis within the bone marrow. MDS compromises innate and adaptive immunity, placing patients at high risk for severe infections, particularly sepsis. Given the aging U.S. population and increasing MDS diagnoses, understanding sepsis-related mortality trends is crucial. Objective: To analyze national trends in sepsis-related mortality among MDS patients (1999–2023), assess demographic disparities, and forecast mortality through 2030. Methods: We analyzed CDC WONDER “Multiple Cause of Death” data (1999–2023), identifying deaths listing both MDS (ICD-10: D46) and sepsis (A41). Age-adjusted mortality rates (AAMR) were calculated per million persons using the 2000 U.S. standard population. Trends were evaluated via Joinpoint regression to estimate Annual Percent Change (APC) and Average Annual Percent Change (AAPC) with 95% confidence intervals (CI). ARIMA models with Box-Cox transformation were fitted after ADF/KPSS tests to forecast AAMR through 2030. Results: From 1999 to 2023, 20,187 sepsis-related deaths occurred among individuals with MDS in the U.S. The overall age-adjusted mortality rate (AAMR) declined from 18.2 per million (95% CI: 16.7–19.6) in 1999 to 16.7 per million (95% CI: 15.6–17.8) in 2023. Males had higher mortality than females, with AAMR decreasing from 28.2 to 23.9; a temporary rise occurred between 2015–2016 (29.0 to 31.8), followed by intermittent rebounds. Female AAMR remained stable, ranging from 10.9 to 13.7, ending at 11.5 in 2023. White individuals experienced the highest number of MDS-associated sepsis deaths (n=17,931), with a relatively stable AAMR of 18.4 in 1999 and 17.6 in 2023. Black individuals saw a modest decline in AAMR from 17.7 to 14.3, accounting for 1,528 deaths. Asian or Pacific Islander individuals, with data available from 2004–2020, had 451 deaths and a significant AAMR decrease from 24.2 to 15.5, indicating notable improvement in this group. In 2023, the Northeast had the highest regional AAMR (21.5), followed by the Midwest (18.9), South (15.2), and West (14.7). Small metro areas had the greatest urbanization-related burden (AAMR 19.3), while large central metros reported lower rates (15.7); rural areas remained disproportionately affected (18.5). ARIMA-based projections forecast a continued rise in MDS-associated sepsis mortality through the end of the decade. The projected AAMRs are 18.72 (95% CI: 15.5–21.6) in 2026, 18.87 (95% CI: 15.7–21.8) in 2028, and 19.02 (95% CI: 15.7–21.8) in 2030. This forecast indicates a plateauing but persistent burden, particularly for high-risk subgroups and underserved regions. Conclusion: Sepsis-related mortality in patients with MDS has steadily increased over the past two decades, with projections indicating continued upward trends through 2030. The disproportionate burden on males, Black individuals, and residents in rural and Southern states highlights the need for improved infection prevention strategies, early recognition, and tailored care delivery for high-risk populations.

3 November 2025 in Blood
Verified
Journal Article
Closed access
HTHaseeb Tareen
Haseeb Tareen
ADAllah Dad
Allah Dad
HAHafsa Ahmed
Hafsa Ahmed
SDSafi Ur Rehman Daim
Safi Ur Rehman Daim
MKManya Kumar
Manya Kumar
VGVenumadhavi Gogineni
Venumadhavi Gogineni
Background: Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that predominantly affect older adults and are characterized by ineffective hematopoiesis, progressive cytopenias, and a heightened risk for progression to acute myeloid leukemia. Cardiovascular complications, particularly heart failure (HF), are increasingly recognized as major contributors to morbidity and mortality in patients with MDS, yet national level data on long-term HF mortality trends in this population remain scarce. Understanding temporal and demographic patterns of HF-related deaths in MDS patients is crucial for risk stratification and developing preventive strategies. Methods: We conducted a retrospective population-based analysis using the CDC WONDER Multiple Cause of Death database to examine HF-related mortality among individuals with MDS between 1999 and 2023. Age-adjusted mortality rates (AAMRs) were calculated per million using U.S. Census data as the denominator. Temporal trends were assessed using Joinpoint regression to determine average annual percent changes (AAPCs). ARIMA models with Box-Cox transformation were fitted after ADF/KPSS tests, with validation by residual checks to forecast future trends from 2024–2030. Subgroup analyses were stratified by sex, race, ethnicity, region, and urbanization level. Results: Between 1999 and 2023, there were 4,947 HF related deaths among individuals with MDS in the United States. Over this period, the AAMR rose from 2.5 per million in 1999 to 2.7 per million in 2023, with notable upward inflections going upto 3 per million in 2007, 2009, 2021 and 2022, however coming back down to 2.7 per million in 2023. Gender-specific trends showed a higher burden in males, whose AAMR increased from 3.9 to 4.1 per million (5% increase), compared to females whose AAMR declined from 1.8 to 1.7 per million (5% decrease). Racial disparities persisted throughout the study period. White individuals accounted for the majority of deaths, with AAMR increasing from 2.7 to 3 per million. Black individuals experienced a more rapid rise, from 1.1 in 1999 to 1.5 in 2023, a 36% increase. Hispanic or Latino individuals saw an increase from 1.2 to 1.3 per million, while non-Hispanic individuals rose from 2.5 to 2.8 per million. Both peaked around 2019-2022 and declined again in 2023. Geographically, the Northeast and Midwest carried the highest burden, peaking at 4.4 and 4.2 per million, respectively, while the South and West exhibited lower yet steadily increasing trends. By 2023, AAMR reached 4.0 in the South and 3.7 in the West. Urbanization analysis revealed the highest AAMRs in small metro (4.3) and micropolitan areas (4.1), while large central metro areas consistently had lower burdens (3.6 in 2023). Based on ARIMA modeling, the AAMR for HF-related mortality in MDS is projected to continue rising steadily. Forecasted rates include 2.64 in 2024, 2.68 in 2026, 2.69 in 2028, and 2.70 per million by 2030 (95% CI: 2.42–3.03), suggesting a persistent but decelerating growth pattern.Conclusion: HF-related mortality among MDS patients in the U.S. has risen markedly over the past two decades, with persistent disparities by sex, race, and geography. Forecasts indicate a continued, albeit plateauing, burden through 2030. These findings suggest the need for targeted cardiovascular risk mitigation strategies in MDS care, particularly in high-risk subgroups.

3 November 2025 in Blood
Verified
Journal Article
Closed access
HTHaseeb Tareen
Haseeb Tareen
ADAllah Dad
Allah Dad
Ali ZubairAli Zubair
Ali Zubair
SBSakshi Bai
Sakshi Bai
MAMuhammad Arham
Muhammad Arham
SMShahzaib Maqbool
Shahzaib Maqbool
Background: Immunoglobulin light chain (AL) amyloidosis is a multisystem disorder resulting from the deposition of misfolded monoclonal light chains produced by clonal plasma cells. Around 10–15% of patients with multiple myeloma (MM) develop coexisting AL amyloidosis, a combination that markedly worsens prognosis due to its impact on vital organs, particularly the heart and kidneys. When MM and AL amyloidosis occur together, overall survival is significantly reduced, often to less than three years in patients with cardiac involvement. Timely diagnosis and coordinated, risk-adapted treatment approaches are essential to improving outcomes in this high-risk population.Methods: Mortality data from CDC WONDER (1999–2023) were analyzed. Deaths describing both MM (ICD-10 C90.0–C90.2) and AL amyloidosis (D76.1–D76.2) were included. Age-adjusted mortality rates (AAMRs; per 100,000) were calculated using the 2000 U.S. standard population. Trends were assessed with Joinpoint regression to calculate the Average Annual Percent Change (AAPC) and 95% confidence intervals (CI). For future projections, ARIMA models with Box-Cox transformation were applied after testing for stationarity using ADF/KPSS tests. Models were validated using residual diagnostics and cross-validation. Subgroup analyses were conducted on the basis of sex, race/ethnicity, U.S. census region, and urbanicity.Results: Between 1999 and 2023, there were 3,519 sepsis-related deaths among individuals with AL amyloidosis and multiple myeloma in the United States. AAMR increased from 3.0 to 3.9 per million, reflecting a 30% rise over the study period (AAPC: +0.85%, 95% CI: +0.50% to +1.20%, p < 0.001). Gender-specific trends revealed a modest AAMR decline in males (25.2 to 24.6 per million; −2.4%), while females experienced a more substantial decline (15.1 to 12.0 per million; −20.5%), with a peak in 2004 followed by a steady downward trajectory. Nevertheless, male mortality remained approximately double that of females in 2023. Racial and ethnic analyses showed that White individuals accounted for the majority of deaths (n=2,874), with AAMR rising from 2.8 to 3.6 per million. Black or African American individuals (n=341) demonstrated a persistently elevated mortality burden, with AAMR increasing from 6.2 in 2013 to 7.2 in 2023. Not Hispanic individuals had 3,349 deaths, with a modest increase in AAMR from 3.1 to 4.0 over the same period. Geographically, the Northeast and Midwest consistently exhibited higher AAMRs, peaking at approximately 4.5 per million in the early 2010s and stabilizing at 3.9 and 3.7 per million, respectively, by 2023. In comparison, the South and West maintained lower rates, ending at 3.3 and 3.1 per million. Urbanization patterns revealed the highest mortality burden in small metro (4.1 per million) and micropolitan areas (3.8 per million), while large central metros had the lowest (3.1 per million). Non-core rural areas maintained elevated mortality (3.9 per million), highlighting disparities in healthcare infrastructure and access. ARIMA forecasting projects a stable trend in sepsis-related mortality among AL amyloidosis patients, with AAMR plateauing at ~3.019 per million in 2026, 2028 and ~3.02 per million in 2030 (95% CI: 2.50–3.46), indicating a persistent but non-worsening burden in the years ahead. Conclusions: Sepsis-related mortality in AL amyloidosis patients has gradually increased over the past two decades, with persistent disparities by gender, race, and geography. Despite improvements in certain subgroups, overall mortality remains elevated, particularly in rural and underserved regions. Projections suggest a stable but ongoing burden, signifying the need for targeted interventions in high-risk populations.

3 November 2025 in Blood
Verified
Journal Article
Closed access
HTHaseeb Tareen
Haseeb Tareen
ADAllah Dad
Allah Dad
ESErum Siddiqui
Erum Siddiqui
MAMuhammad Arham
Muhammad Arham
MKManya Kumar
Manya Kumar
AIAhmad Iftikhar
Ahmad Iftikhar
Background: Patients with aplastic anemia (AA) are at increased risk of sepsis-related mortality due to underlying immunosuppression and bone marrow failure. Despite advances in treatment, sepsis remains a leading cause of death in this population. This study analyzes trends in sepsis-related mortality among AA patients in the U.S. from 1999 to 2023, with a focus on disparities by sex, race/ethnicity, geographic region, and urbanization status, and forecasts mortality trends through 2030. Methods: Age-adjusted mortality rates (AAMR) were calculated using national mortality data from the CDC WONDER database. Records were filtered to include deaths with ICD-10 code D61 (Aplastic Anemia) and ICD-10 code A41 (Sepsis) listed among the multiple causes of death. Temporal trends were identified using Joinpoint regression analysis, and future mortality rates were projected using ARIMA modeling. Stratified analyses were performed by sex, census region, state, race/ethnicity, and level of urbanization. Statistical significance was determined at a threshold of p < 0.05. Results: From 1999 to 2023, a total of 20,436 sepsis-related deaths occurred among AA patients. The AAMR initially declined from 19.1 (95% CI: 17.6–20.6) in 1999 to 16.3 (95% CI: 15.0–17.6) in 2001 but rose to 23.0 (95% CI: 21.8–24.3) by 2023. Males consistently exhibited higher mortality rates than females, with rates of 27.9 and 19.3, respectively, in 2023. Marked geographic disparities were observed, with the South recording the highest AAMR (24.9 in 2023), and states such as Kentucky (27.1) and Texas (26.1) exceeding the national average. Racial and ethnic analyses revealed persistently elevated mortality among Black individuals (25.8 in 2023), while Asian/Pacific Islanders experienced early declines followed by later increases. Urban-rural trends varied, with micropolitan areas peaking at an AMR of 23.8 (95% CI: 19.5–28.1) in 2020. Forecasts for 2021–2030 project stable but uncertain mortality trends, with an estimated AAMR of 19.5 (95% CI: 11.38–27.22) by 2030. Conclusion: Sepsis-related mortality among AA patients has increased significantly since the early 2000s, with pronounced disparities by sex, race, and geographic regions. The sustained rise, particularly among males and in Southern states highlights critical gaps in prevention and clinical management. Projections indicate no near-term improvement, emphasizing the urgent need for targeted interventions in high-risk populations.